Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.

Authors
  • Ridker, Paul M1
  • MacFadyen, Jean G
  • Glynn, Robert J
  • Chasman, Daniel I
  • 1 Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA. [email protected]
Type
Published Article
Journal
Circulation Cardiovascular Genetics
Publisher
Ovid Technologies Wolters Kluwer -American Heart Association
Publication Date
Jun 01, 2011
Volume
4
Issue
3
Pages
312–317
Identifiers
DOI: 10.1161/CIRCGENETICS.110.959353
PMID: 21493817
Source
Medline
License
Unknown

Abstract

In the large primary prevention JUPITER trial, rosuvastatin was equally effective at reducing cardiovascular event rates among carriers and noncarriers of the KIF6 719Arg allele. Thus, at least for rosuvastatin, there appears to be no clinical utility to screening for KIF6 genotype as a method to determine vascular risk or to predict statin efficacy. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

Report this publication

Statistics

Seen <100 times